Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group
about
Why prevent, diagnose and treat congenital toxoplasmosis?Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot studyEvaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replicationTreatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine.Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restriPharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazineAzithromycin for ocular toxoplasmosis.Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North AmericaPopulation pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosisChorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis StudyPrematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009)Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii.New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.Clinical manifestations of ocular toxoplasmosis.Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDSPopulation pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.Reply to Wallon and Peyron.Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study.Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims Toxoplasmosis Group.
P2860
Q22305913-237E7C31-1A76-4997-8B0D-BC7B8E547492Q28275227-A572C046-C04E-4B60-9611-C5542B253D2FQ28748825-B1DC2E16-7923-4FC7-B430-0DBF70554682Q33368207-64CD6372-4E94-490D-BC13-939B056A9343Q34043532-8BD1DC1A-EF0C-45FE-9E10-EB4AA02A7B14Q34142328-6A66A0B5-1571-40DE-ABCE-BF427B824602Q34439215-9F9462FC-4A2A-4D29-AA20-3D26D64E7B15Q34737758-C84C6099-936A-479C-89BB-9A5685B86AEFQ35110989-90790130-9A99-4CAA-9272-F2A9226D0031Q35302808-66D39CF1-2525-4B80-B4DE-A6FE583E2767Q35636528-4E36B7DC-14C5-4D19-964A-D534DA404A5DQ35826163-FE9E46EB-43FE-43F0-8A79-B43049BDF148Q35945424-9918CB91-7449-43B8-A7BF-F209CAFE857EQ35948790-64D35833-4C25-485A-9DAF-ADC09EADD520Q36396820-66718A02-A952-4CE1-9C73-DC083EBCAA03Q37093155-1C332AE1-E230-4569-A040-291EC040E596Q37128281-22E7BFFD-A3A2-417E-B34F-F9A437A025B9Q37856265-B4C3FDEE-54B8-45B2-BF02-441C6651FB45Q39782411-3B7D77A2-8B23-4F7E-8141-70F37A10E5F4Q40165651-BC47A419-352B-4D92-BA99-F578DE170A63Q41831157-98B932CA-6EA0-4386-B515-9E10E3B404E5Q42612923-11A2F373-395B-4590-81B3-922446536EDFQ50465649-4C98CDA4-8137-4499-A949-288B875CC9F8Q55068083-08EA47D8-51E3-4D1B-8282-7FC00DEFAB48
P2860
Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Levels of pyrimethamine in ser ...... sis. Toxoplasmosis Study Group
@ast
Levels of pyrimethamine in ser ...... sis. Toxoplasmosis Study Group
@en
type
label
Levels of pyrimethamine in ser ...... sis. Toxoplasmosis Study Group
@ast
Levels of pyrimethamine in ser ...... sis. Toxoplasmosis Study Group
@en
prefLabel
Levels of pyrimethamine in ser ...... sis. Toxoplasmosis Study Group
@ast
Levels of pyrimethamine in ser ...... sis. Toxoplasmosis Study Group
@en
P2093
P2860
P921
P356
P1476
Levels of pyrimethamine in ser ...... sis. Toxoplasmosis Study Group
@en
P2093
P2860
P304
P356
10.1128/AAC.36.5.1040
P407
P577
1992-05-01T00:00:00Z